Two or four days after intravenous injections of labeled amino-acids, the inhibitor was isolated by the method previously described;3 its specific activity was approximately 1,700. The radioactivity of the 'purified' inhibitor was determined,5 and the results obtained are summarized in Table 1 . The hydrolysate of the inhibitor was radiochromatographed. 6 The chromato gram of the hydrolysates seemed to show radioactivity essentially in the methionine and cystine positions (Fig. 1) . Methionine given intravenously was in part transformed into cystine and incorporated into the inhibitor. 7 The appearance of methionine oxides (methionine sulfoxide and methionine sulfone) and cysteic acid in the radiochromatograph seemed to be due to the oxidation of methionine and cystine during hydrolysis of the inhibitor with hydrogen chloride. The distribution of radioactivity in the hydrolysed inhibitor is shown in Table  2 . In the inhibitor, approximately 87 per cent of radioactivity was found in methionine and approximately 13 per cent in cystine.
A qualitative analysis by automatic amino-acid analyser of constituent amino acids of the inhibitor after hydrolysis clearly revealed the presence of Cys, Met, Asp, Thr, Ser, Glu, Pro, Ala, Gly, Val, Leu, Ileu, Phe, Lys, His, Arg and H0 pro. The inhibitor itself also showed a positive staining with platinum chloride or with nitroprusside followed by sodium cyanide." The observations just presented indicate that 35S-methionine or 35S-cystine is incorporated into a specific protease inhibitor and that they are actually constituent amino-acids of this polypeptide. Furthermore, the observations would suggest a possibility that the local increase of this polypeptide in parallel with the subsiding inflammatory process may be associated with the synthesis of this substance in the inflamed skin site. This possibility seems very important for the proteolytic mechanism in inflammation. 
